Skip to main content

Develop Novel Medicines for Once Monthly Intranasal Administration Designed to Mitigate Clinical Symptoms Associated With Respiratory Diseases

Printer-friendly versionPrinter-friendly versionSend by emailSend by email
Award date: 
Sep 11, 2015
Award amount: 
$150,000
Organization name: 
Symmune Therapeutics, LLC
Principal Investigator: 
Lyman, Scott
Grant program category: 
Business Financing
Grant program name: 
Small Business Research Loan
Region: 
Research Triangle

Symmune Therapeutics is developing medicines designed to mitigate clinical symptoms associated with respiratory diseases, including, respiratory tract infections, allergic rhinitis, and asthma. The target product profile is a dry powder medicine for once monthly intranasal administration.

Fiscal year: 
2016